FDA Approves New Weight-Loss Product

The U.S. Food and Drug Administration (FDA) has approved Plenity, a new prescription weight-loss product for people who are ineligible for gastric bypass surgery.


Intended for use as a weight-loss aid in those with a body-mass index (BMI) of 25-40 kg/m2, the product is “an oral superabsorbent biodegradable hydrogel that expands in the stomach to create pressure on the stomach walls and increase the feeling of satiety.” According to Time, the capsules can fill roughly a quarter of the stomach without contributing any calories. In a clinical trial, 59 percent of patients receiving the product achieved at least a 5 percent weight loss.

Pricing has not yet been set for Plenity, which is expected to launch in the second half of 2019 and become widely available in 2020.

Want to learn more about weight management? Read “Tried and True Weight-Loss Techniques,” “Strategies for Weight Management,” and “Why Can’t I Lose Weight?”

Learn more about the health and medical experts who who provide you with the cutting-edge resources, tools, news, and more on Diabetes Self-Management.
About Our Experts >>